AN2 Therapeutics, Inc.
ANTX
$5.73
-$0.25-4.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -36.28M | -34.55M | -35.17M | -33.99M | -37.38M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.13M | 4.95M | 5.18M | 5.11M | 5.69M |
| Change in Net Operating Assets | 1.46M | -1.68M | 164.00K | -991.00K | -3.81M |
| Cash from Operations | -30.68M | -31.28M | -29.83M | -29.87M | -35.50M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.91M | 27.41M | 28.31M | 14.26M | 26.87M |
| Cash from Investing | 17.91M | 27.41M | 28.31M | 14.26M | 26.87M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 39.11M | 37.38M | 113.00K | 113.00K | 88.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -248.00K | -- | -- | -- | -- |
| Cash from Financing | 38.87M | 37.38M | 113.00K | 113.00K | 88.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.10M | 33.50M | -1.41M | -15.50M | -8.55M |